Literature DB >> 18337605

EGFR antagonists in cancer treatment.

Fortunato Ciardiello1, Giampaolo Tortora.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18337605     DOI： 10.1056/NEJMra0707704

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  701 in total

1.  Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.

Authors:  J-I Lai; Y-C Lai; Y-C Chen; N-K Wang; J-N Pan; W-S Wang; S-C Chang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

Review 2.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

3.  Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.

Authors:  Sheldon R Mink; Surabhi Vashistha; Wenxuan Zhang; Amanda Hodge; David B Agus; Anjali Jain
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

Review 4.  Rosacea: The cytokine and chemokine network.

Authors:  Peter Arne Gerber; Bettina Alexandra Buhren; Martin Steinhoff; Bernhard Homey
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

5.  Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.

Authors:  Yanru Wang; Jennifer A Freedman; Hongliang Liu; Patricia G Moorman; Terry Hyslop; Daniel J George; Norman H Lee; Steven R Patierno; Qingyi Wei
Journal:  Int J Cancer       Date:  2017-06-01       Impact factor: 7.396

Review 6.  Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

Authors:  Cristiana Lo Nigro; Vincenzo Ricci; Daniela Vivenza; Cristina Granetto; Teresa Fabozzi; Emanuela Miraglio; Marco C Merlano
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Authors:  Shai Rosenberg; Maïté Verreault; Charlotte Schmitt; Justine Guegan; Jeremy Guehennec; Camille Levasseur; Yannick Marie; Franck Bielle; Karima Mokhtari; Khê Hoang-Xuan; Keith Ligon; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

8.  Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).

Authors:  Brittany L Carpenter; Min Chen; Teresa Knifley; Kelley A Davis; Susan M W Harrison; Rachel L Stewart; Kathleen L O'Connor
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

Review 9.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

10.  MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1).

Authors:  Defang Sun; Feng Yu; Yutao Ma; Ran Zhao; Xi Chen; Jie Zhu; Chen-Yu Zhang; Jiangning Chen; Junfeng Zhang
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.